Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Amira Pharmaceuticals logo — company profile

Amira Pharmaceuticals

Founded 2005 15 employees Series B Total: $32.00M Biotechnology, Health Care +1

General Information

Company Name Amira Pharmaceuticals
Founded Year 2005
Employees 15
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series B
Business Model B2B
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Amira Pharmaceuticals. To contact Amira Pharmaceuticals, visit amirapharm.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Amira Pharmaceuticals compare?

A PDF of Amira Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Amira Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Amira Pharmaceuticals

Amira Pharmaceuticals is a forward-thinking player in the Biotechnology and Pharmaceutical sectors, founded in 2005. The company is dedicated to the discovery and development of small molecule drugs targeting inflammatory diseases.

By leveraging its expertise in bioactive lipid pathways and signaling processes, Amira Pharmaceuticals aims to revolutionize treatments for conditions like asthma, chronic obstructive pulmonary disease, and fibrotic diseases. Its focus on early-stage innovation places it in a unique position to address unmet medical needs.

The company secured a significant $25.00M Series B investment on March 23, 2007. This round was backed by notable investors including Novo Holdings, Avalon Ventures, Prospect Venture Partners, and Versant Ventures. This funding underscores investor confidence in Amira Pharmaceuticals' strategic approach and potential for high-impact breakthroughs in inflammatory disease treatment.

Business keywords: Pharmaceuticals, Small molecule drugs, Inflammatory disease, Drug discovery, Bioactive lipid pathways, Chronic obstructive pulmonary disease, Asthma treatment, Cardiovascular diseases, Fibrotic diseases, Early drug development

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $25.00M 4
Novo Holdings Avalon Ventures Prospect Venture Partners
Novo Holdings, Avalon Ventures +2
23 Mar 2007
Series A $4.00M 3
Avalon Ventures Prospect Venture Partners Versant Ventures
Avalon Ventures, Prospect Venture Partners +1
01 Nov 2006
Series A $3.00M 3
Avalon Ventures Prospect Venture Partners Versant Ventures
Avalon Ventures, Prospect Venture Partners +1
10 Aug 2005

Amira Pharmaceuticals Alternatives & Competitors

View All Alternatives
Amira Pharmaceuticals vs
BioLum Sciences
BioLum Sciences United States

Transforming Precision Drug Discovery and Early Detection of Disease

Grant
5 employees
Biotechnology, Digital Health
Amira Pharmaceuticals vs
Tvardi Therapeutics
Tvardi Therapeutics United States

Breakthrough Medicines for Cancer, Chronic Inflammation & Fibrosis

Series B
18 employees
Biotechnology, Health Care
Amira Pharmaceuticals vs
TNF Pharmaceuticals, Inc.
TNF Pharmaceuticals, Inc. United States

TNF Pharmaceuticals is a clinical stage pharmaceutical company committed to extending a healthy life...

Post-IPO Equity
10 employees
Biotechnology, Pharmaceutical
Also compare with: Amira Pharmaceuticals vs Apellis Pharmaceuticals Apellis Pharmaceuticals View all alternatives

FAQ About Amira Pharmaceuticals

Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many condition...
Amira Pharmaceuticals was founded in 2005.
Amira Pharmaceuticals operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Pharmaceuticals, Small molecule drugs, Inflammatory disease and Drug discovery.
Amira Pharmaceuticals has a B2B business model. Its revenue comes from Licensing and Product Sales.
Amira Pharmaceuticals has approximately 15 employees.
Amira Pharmaceuticals has completed 3 funding rounds, raising a total of $32.00M. The latest funding stage is Series B.
Top alternatives and competitors to Amira Pharmaceuticals include BioLum Sciences, Tvardi Therapeutics, TNF Pharmaceuticals, Inc., Encysive Pharmaceuticals, Nextera AS. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Amira Pharmaceuticals and BioLum Sciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Amira Pharmaceuticals, https://bouncewatch.com/company/amira-pharmaceuticals, updated 14 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout